Potelligent will be used in return for upfront and milestone fees.



KaloBios licensed BioWa’s Potelligent® technology to enhance the antibody-dependent cellular cytotoxicity (ADCC) of certain antibodies.


Under the terms of the agreement, KaloBios has nonexclusive rights to research, develop, and commercialize therapeutic antibodies generated through Potelligent technology. In return, BioWa will receive an upfront payment and may receive development milestone fees and royalties on products.


Potelligent technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a fucosyltransferase-knockout CHO cell line as a production cell. Research shows that Potelligent technology enhances ADCC activity of an antibody in vitro and significantly increases potency and efficacy of the antibody in vivo, according to BioWa.








This site uses Akismet to reduce spam. Learn how your comment data is processed.